Nektar TherapeuticsNKTRNASDAQ
Loading
EV to Sales HistoryNormalizing
Percentile Rank71
3Y CAGR+44.7%
5Y CAGR-4.7%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
+44.7%/yr
vs +0.3%/yr prior
5Y CAGR
-4.7%/yr
Recent acceleration
Acceleration
+44.4pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthNormalizing
PeriodValueYoY Change
202515.34+504.9%
20242.54+20.3%
20232.11-58.4%
20225.06-80.1%
202125.46+30.3%
202019.54-45.3%
201935.68+612.9%
20185.00-83.9%
201731.05+170.1%
201611.49-